Lenalidomide in Combination With R-GemOx in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.
Diffuse Large B Cell Lymphoma
DRUG: Lenalidomide
Maximum tolerated dose, Maximum tolerated dose, at the end of the first cycle of R2-GemOx (each cycle is 14 days)|Dose limiting toxicity, Dose limiting toxicity, 28 days|Dose limiting toxicity, Dose limiting toxicity, 2 years
progression-free survival, progression-free survival, 2 years|overall survival, overall survival, 2 years
Gemcitabine and Oxaliplatin(GemOx) shows effective activity in patients with relapsed diffuse large-cell lymphoma and other solid tumors. The purpose of this study is to investigate efficacy and safety of Lenalidomide in combination with R-GemOx as first-line treatment of elderly patients with Diffuse large B cell lymphoma.